Document is current
Any future updates will be listed below
-
Authors
Koto, Ruriko https://orcid.org/0000-0001-9201-1273
Sato, Izumi
Kuwabara, Masanari
Seki, Tomotsugu
Kawakami, Koji https://orcid.org/0000-0002-7477-4071
- License Information
-
More Information
Article History
Received: 6 October 2021
Revised: 23 December 2021
Accepted: 15 January 2022
First Online: 24 January 2022
Declarations
:
: RK is an employee of Teijin Pharma Limited. IS has received consulting fees from Novartis Pharma K.K.; and holds stock in Daiichi Sankyo Company, Ltd.; Astellas Pharma Inc.; and AbbVie Inc. MK and TS declare no conflicts of interest. KK has received research funds from Eisai Co., Ltd.; Kyowa Kirin Co., Ltd.; Sumitomo Dainippon Pharma Co., Ltd.; Pfizer Inc.; Stella Pharma Corporation; CMIC Co., Ltd.; Suntory Beverage & Food Ltd.; Mitsubishi Corporation, and Real World Data Co., Ltd.; consulting fees from Leber Inc.; JMDC Inc.; Shin Nippon Biomedical Laboratories Ltd.; Kaken Pharmaceutical Co., Ltd.; and Advanced Medical Care Inc.; executive compensation from Cancer Intelligence Care Systems; Inc.; honoraria from Mitsubishi Chemical Holdings Corp., Mitsubishi Corp., and Pharma Business Academy; and holds stock in Real World Data Co., Ltd.
